RCS - hVIVO PLC - EUR3.2m Venn contract with global pharma client

hVIVOAnnouncement

17/01/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230117:nRSQ8912Ma&default-theme=true

RNS Number : 8912M  hVIVO PLC  17 January 2023

 

hVIVO plc

("hVIVO" or the "Company")

 

€3.2m contract for Venn Life Sciences with global pharmaceutical client

For provision of pharmacokinetic and programming services

 

hVIVO plc (AIM & Euronext: HVO) (formerly Open Orphan plc), a rapidly
growing specialist contract research organisation (CRO) and world leader in
testing infectious and respiratory disease products using human challenge
clinical trials, announces its consultancy services division, Venn Life
Sciences (https://www.vennlifesciences.com/) ("Venn"), has signed a contract
with a major global pharmaceutical client worth €3.2m over two years.

 

The contract commences in January 2023, with the Venn team in Breda providing
dedicated complex clinical pharmacokinetics ("PK") consultancy and programming
services to this global pharmaceutical client on a number of drug development
programmes across multiple therapeutic areas, to study the absorption,
distribution and excretion of drugs within the body.

 

Venn has nearly 30 experts dedicated to providing PK and programming services
to clients and has been a trusted partner to the pharma industry for over 25
years. These services cover a diverse range of trials and therapeutic areas
ranging from traditional phase I trials to more complex and challenging
trials, such as oncology and ATMP (Advanced Therapy Medicinal Product) trials.
Venn is a leader in providing fully integrated drug development services from
early drug discovery to clinical trials. Its offering includes drug
development consultancy, clinical trial design and execution services with
expertise and capabilities in CMC (Chemistry, Manufacturing and Controls),
Non-Clinical, Clinical Pharmacology and Development, Statistics, Study Design
and Methodology, Data Management, Medical Writing and Regulatory Affairs.
These combined services enable Venn to provide its clients with a complete
end-to-end service on all stages of their drug development programmes, from
the early planning phase to final execution. Venn has offices in Breda
(Netherlands) and Paris (France).

 

Yamin 'Mo' Khan, Chief Executive Officer of hVIVO, said: "The consultancy
work included in this two-year contract highlights the continued expansion of
our pharmacokinetic and programming services as part of Venn's integrated drug
development services provision. Venn's outstanding expertise and reputation in
the industry over the past 25 years makes them a go-to partner. In addition,
for infectious disease products, hVIVO and Venn have also been able to conduct
projects from discovery to Phase II Challenge Studies, something no one else
can offer."

 

Dr Katsuhiro Mihara, Head of Clinical Development of Venn Life Sciences,
commented: "This contract is a great example of Venn's ability to deliver on
long term PK and programming projects. We have worked closely with hVIVO to
identify ways to leverage this strong client base, to drive both upselling and
cross-selling opportunities, and find even greater synergies between the two
integrated clinical services businesses."

 

For further information please contact:

 

 hVIVO plc                                       +44 (0) 20 7756 1300
 Yamin 'Mo' Khan, Chief Executive Officer

 Stephen Pinkerton, Chief Financial Officer

 Liberum Capital (Nominated Adviser and Joint Broker)                       +44 (0) 20 3100 2000
 Ben Cryer, Edward Mansfield, Phil Walker, Will King

 finnCap plc (Joint Broker)                                                +44 (0) 20 7220 0500
 Geoff Nash, Charlie Beeson, Nigel Birks, Harriet Ward (ECM)

 Davy (Euronext Growth Adviser and Joint Broker)                           +353 (0) 1 679 6363
 Anthony Farrell, Niall Gilchrist

 Walbrook PR (Financial PR & IR)                 +44 (0) 20 7933 8780 or hvivo@walbrookpr.com

 Stephanie Cuthbert / Phillip Marriage /         +44 (0) 7796 794 663 / +44 (0) 7867 984 082 /

Louis Ashe-Jepson
+44 (0) 7747 515 393

 

 

Notes to Editors

 

hVIVO plc (ticker: HVO) (formerly Open Orphan plc) is a rapidly growing
specialist contract research organisation (CRO) and the world leader in
testing infectious and respiratory disease vaccines and therapeutics using
human challenge clinical trials. The Group provides end-to-end early clinical
development services to its large, established and growing repeat client base,
which includes four of the top 10 largest global biopharma companies.

 

The Group's fast-growing services business includes a unique portfolio of 10+
human challenge models to test a broad range of infectious and respiratory
disease products, world class challenge agent manufacturing, specialist drug
development and clinical consultancy services via its Venn Life Sciences
brand, and a lab offering via its hLAB brand, which includes virology,
immunology biomarker and molecular testing. The Group offers additional
clinical field trial services such as patient recruitment and clinical trial
site services.

 

hVIVO runs challenge studies in London from its Whitechapel quarantine
clinic, its state-of-the-art QMB clinic with its highly specialised on-site
virology and immunology laboratory, and its clinic in Plumbers Row. To recruit
volunteers / patients for its studies, the Company leverages its unique
clinical trial recruitment capacity via its FluCamp
(https://eur05.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.flucamp.com%2F&data=05%7C01%7CCarol.Dalton%40openorphan.com%7Cfb9f1a50aaa9492d81ed08da875cca71%7C131abc777e104bbd90170559abc5d601%7C1%7C0%7C637971129881295595%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=fQdtQTHu9Bo70yRgWcZW5liNTXPYiWl9YayUA01E%2FlA%3D&reserved=0)
 volunteer screening facilities in London and Manchester.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRABRGDBUDBDGXL